ArticleGynecology and minimally invasive therapy
The Efficacy of Polyacrylamide Hydrogel (Bulkamid) Transurethral Injection System: The Outcome of Short-term Follow-up of 100 Cases.
Article in Gynecology and minimally invasive therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrogel-Based Therapies for Female Stress Urinary Incontinence: From Bulking Agents to Regenerative Platforms-A Narrative Review.Current urology reports · 2026Review
- Symptom Relief and Practice Setting Variation in Bulkamid Injections for Stress Urinary Incontinence.Neurourology and urodynamics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The injection of transurethral bulking agents is an office procedure that has been used as a primary and secondary treatment to improve urethral coaptation and restore urinary continence. The treatment has been available in the US since January 2020. In this study, we aim to present our experience with the efficacy of Bulkamid transurethral injection as a primary and secondary treatment among women with stress urinary incontinence (SUI) or mixed urinary incontinence. Materials and Methods: This is a retrospective study that was performed on 100 patients who received Bulkamid as primary or secondary treatment. The data were collected by reviewing medical records. The procedure was performed in the office with the injection of local anesthesia. The patients were followed up approximately 30 days after the procedure and the efficacy of Bulkamid injection was evaluated. Results: One hundred patients were evaluated upon returning to the office. The mean age of patients was 62 years, and the mean body mass index was 29. Forty-eight patients have received Bulkamid treatment for stress incontinence as a primary procedure and 49 as a salvage procedure. The mean satisfaction reported by the patients was 53.7% for the primary group and 69.69% for the secondary group, with a Conclusion: Bulkamid transurethral injection appears to be a safe and effective treatment option for women with primary and secondary SUI. There is a trend toward higher short-term satisfaction in patients with previous anti-incontinence procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.